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Background: To reduce the duration and overall costs of cardiovascular trials, use of the combined endpoints
in trial design has become commonplace. Though this methodology may serve the needs of investigators and
trial sponsors, the preferences of patients or potential trial subjects in the trial design process has not been
studied.
Objective: To determine the preferences of patients in the design of cardiovascular trials.
Design: Participants were surveyed in a pilot study regarding preferences among various single endpoints
commonly used in cardiovascular trials, preference for single vs. composite endpoints, and the likelihood of
compliance with a heart medication if patients similar to them participated in the trial design process.
Participants: One hundred adult English-speaking patients, 38% male, from a primary care ambulatory
practice located in an urban setting.
Key results: Among single endpoints, participants rated heart attack as significantly more important than
death from other causes (4.53 vs. 3.69, p0.004) on a scale of 16. Death from heart disease was rated as
significantly more important than chest pain (4.73 vs. 2.47, pB0.001), angioplasty/PCI/CABG (4.73 vs. 2.43,
pB0.001), and stroke (4.73 vs. 2.43, pB0.001). Participants also expressed a slight preference for combined
endpoints over single endpoint (43% vs. 57%), incorporation of the opinions of the study patient population
into the design of trials (48% vs. 41% for researchers), and a greater likelihood of medication compliance if
patient preferences were considered during trial design (67% indicated a significant to major effect).
Conclusions: Patients are able to make judgments and express preferences regarding trial design. They prefer
that the opinions of the study population rather than the general population be incorporated into the design
of the study. This novel approach to study design would not only incorporate patient preferences into medical
decision making, but it also has the potential to improve compliance with cardiovascular medications.
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C
linical trials play a pivotal role in clinical medi-
cine, guiding the practice of medicine and the
development of new guidelines. The design of
clinical trials and the choice of trial endpoints have sig-
nificant financial impact on the overall cost of the trial.
To reduce the cost and duration of clinical trials, use of
composite endpoints, in which at least two component
outcomes are combined into a single composite outcome,
has become a popular choice for trial design in almost all
fields of clinical medicine. The main advantages support-
ing the use of composite outcomes are as follows (1):
. The sample size can be reduced because of the higher
number of events available in a composite outcome
compared to a single outcome. As overall medical care
has advanced over the past two decades, the general
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ovascular disease has resulted in a higher number of
patients who must now be enrolled in cardiovascular
trials in order to demonstrate a mortality benefit and
avoid a Type I error.
. The duration of the clinical trial can be reduced.
. Costs of the clinical trial can be substantially reduced,
resulting in more trials conducted for a given amount
of investment. Indeed, it is estimated that phase 3
clinical trials in 2006 cost $26,000 per patient, and the
rate is increasing at a rate of 4.6% per year (2).
. More rapid demonstration of the efficacy of a novel
treatment can make a new drug more readily available
to those in need.
. Investigators can avoid needing to choose a single
endpoint to study. A single disease process can result
in several important separate endpoints, such as heart
attacks and strokes.
Because of these potential benefits, use of composite
outcomes as a study design methodology has become
commonplace in landmark, practice-changing clinical
trials, as randomized controlled trials have become the
new standard. In a review of 1,231 cardiovascular clinical
trials conducted from 2000 to 2007, 37% used composite
endpoints (3). Ideally, component outcomes should each
be clinically meaningful, share the same biological effect
or mechanism of action, contribute equally to the com-
posite, and viewed with a similar degree of importance
by patients (3). Unfortunately, those standards are not
closely followed. In a review of 84 cardiovascular trials
that used composite endpoints, 54% used endpoints with
a wide range of importance to patients (4). The authors
note that this practice may yield misleading impressions
of the overall impact of the novel treatment, since higher
event rates and larger treatment effects are associated
with less important endpoints, such as hospitalization
for chest pain, whereas more important endpoints, such
as death due to myocardial infarction, were generally
associated with lower event rates. Another author found
inconsistent use of the composite endpoint approach
across clinical trials, with flaws existing in both the
methodology as well as the reporting of results (5), while
another lamented, ‘The use of composite outcomes in
trials is problematic. Components are often unreasonably
combined, inconsistently defined, and inadequately re-
ported. These problems will leave many readers confused,
often with an exaggerated perception of how well in-
terventions work’ (5).
A key but unrepresented party in the trial design
decision-making process is the general public. Though
patients, whose treatment is the ultimate goal of medical
research, are the most important stakeholders in the design
of clinical trials, they have not had a voice in the selec-
tion of trial design or the specific component endpoints.
We hypothesize that members of the general public can
and desire to have a voice in the design of clinical trials.
Yet, no studies have addressed patients’ preferences re-
garding the use of composite endpoints or the selection of
the individual component endpoints. Such a study would
not only provide valuable insight into patient preferences,
but would also demonstrate that lay patients can under-
stand study design methodology and express preferences.
Methods
Adult patients from a primary care practice were asked
to participate in a pilot study and express their opinions
regarding use of endpoints in contemporary cardiovas-
cular research trials. The study protocol was reviewed and
approved by MedStar Health Institutional Review Board.
Study design
Ambulatory patients were recruited from the patient
population of an outpatient primary care office located
in an urban setting. Consecutive patients were ap-
proached until the target of 100 participants was reached.
A study coordinator administered a questionnaire to
active participants and was available to answer questions
if participants did not understand any portion of the
survey. The initial part of the questionnaire included
questions regarding demographic information (age, gen-
der, ethnicity, and level of education). Patients were also
asked if they had enrolled in any trial/s in the past and, if
yes, then brief details regarding that trial were given.
In the latter part of the questionnaire, participants’
opinions regarding various endpoints commonly used in
cardiovascular trialswere requested. With abrief explana-
tion about what a single and composite endpoint means,
their preferences were solicited for single vs. composite
endpoints, how a research study/trial should be designed,
and how likely they would be to take a particular heart
medication if they knew that patients similar to them
participated in the decision-making process of selecting
the trial endpoints that proved the medication to be
efficacious.
The criteria for inclusion and exclusion are listed
below.
Inclusion criteria
Adults aged 18 years or older who are able to read and
understand the questionnaire were included in the study.
Exclusion criteria
1) Children and adolescents (age 18 years or younger)
2) Patients who cannot read English
3) Patients who are unable to understand the
questionnaire.
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pants. The responses were summarized using frequencies
and percentages for categorical variables, and means and
standard deviations for the continuous variables. Statis-
tical comparisons between the rating scores for selected
endpoints were made using paired t-tests for continuous
variables and proportions tests for matched data for
categorical variables. A copy of the survey is provided in
the Supplementary file.
Results
The demographic distribution of the sample population is
listed in Table 1.
The participants were generally above 40 years of age,
with Caucasians (52%) and African Americans (42%)
comprising the major ethnic groups in the study. This is
typical of the age group targeted by most cardiovascular
trials. However, the ethnic distribution varies consider-
ably among such trials, but most have far less African
American participants. Approximately 75% of the sample
population attended at least 2 years of college (Table 2).
Eleven percent of participants had participated in one
or more clinical trials in the past. Though this number is
low, those who have had experience with clinical trials
in the past would presumably have enriched knowledge
about clinical trials.
Table 3 lists the results of patients’ perceptions of the
importance of commonly used endpoints. Patients scored
each endpoint on a scale from 1 to 6, with ‘1’representing
‘least important’ and ‘6’ representing ‘most important’.
Most of the participants indicated that heart attack
and death from heart disease were the most important
endpoints to be included in a cardiovascular trial. Heart
attack was rated as significantly more important than death
from other causes (4.53 vs. 3.69, p0.004), chest pain
(4.73 vs. 2.47, pB0.001), angioplasty/PCI/CABG (4.73
vs. 2.43, pB0.001), and stroke (4.73 vs. 2.43, pB0.001).
Death from heart disease was also rated higher in import-
ance than death from other causes (4.53 vs. 3.69, p
0.004), chest pain (4.53 vs. 2.47, pB0.001), angioplasty/
PCI/CABG (4.53 vs. 2.43, pB0.001), and stroke (4.53 vs.
2.43, pB0.001).
These findings suggest that patients prioritize the
endpoints of heart attack and cardiovascular death in
cardiovascular trials. In addition, the choice of these two
endpoints may reflect the general concern in the popula-
tion about the importance of these two conditions, and
perhaps the uncertainty regarding the relevance of death
from other causes as an endpoint in cardiovascular trials.
Coronary revascularization and hospitalization for chest
pain were relatively least important in comparison to
the endpoints of cardiovascular death and heart attack.
Notably, patients do not value all of these endpoints as
being equivalent in importance, though clinicians and
researchers treat all of the endpoints as equivalent in a
composite endpoint analysis.
Table 4 lists the responses regarding a hypothetical
cardiovascular trial comparing the efficacy of two cardio-
vascular medications.
In evaluating potential endpoints for this trial, nearly
all participants selected heart attack as an endpoint that
should be included in the trial design. A significantly
higher proportion of respondents selected heart attack
as an endpoint compared to death from heart disease
Table 1. Demographic characteristics of the sample
population
N100 %
Male 38
Age groups
1830 5
3040 9
4050 7
5060 27
6070 32
70 20
Ethnicity
Asian 4
Caucasian 52
African American 42
Hispanic 2
Others 0
Level of education
High School/GED 26
2 years of college 20
4 years of college 18
Graduate school 36
Table 2. Participation in a clinical trial in the past
Participation in trial Number of participants
No 89
Yes 11
Total 100
Table 3. Patient perception of the importance of common
endpoints
Endpoint/importance Mean score (SD) (95% CI)
Heart attack 4.53 (1.49) (4.24.8)
Death (heart disease) 4.73 (1.42) (4.55.0)
Death (other cause) 3.69 (1.78) (3.34.0)
Chest pain-hosp. 2.47 (1.24) (2.22.7)
Angioplasty/PCI/CABG 2.43 (1.18) (2.22.7)
Stroke 3.15 (1.53) (2.93.5)
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CABG (pB0.001), and stroke (pB0.001). Stroke was
selected as significantly important more times compared
to angioplasty/PCI/CABG (pB0.007) but not compared
to chest pain and death from heart disease. The parti-
cipants were more or less equivocal regarding the other
proposed endpoints.
Participants were then surveyed regarding their choice
of either a single or a composite endpoint. The results are
provided in Table 5.
Participants expressed a preference for composite end-
points over single endpoints (57% vs. 43%). This result
might be due to an inability to select a particular single
endpoint over another (e.g., heart attack over death from
heart disease).
Participants were then asked who should have input
into the design of cardiovascular trials. The results are
found in Table 6.
More participants recommended taking into account
the opinions of the patient population (48%) over
researchers/scientists (41%) or the general population
(11%) in the decision-making process of trial design. At
present, the trials are designed without input from the
patient population or the general public, but solely by
research investigators. If patients’ preferences for selec-
tion of endpoints are considered, it is possible that study
design would be significantly different from what is
currently being selected by trial researchers.
Finally, participants were surveyed to see if their
potential compliance to a cardiovascular medication
would be affected if like-patients had contributed to the
decisions regarding trial design of the trial. The results
can be found in Table 7.
Participants acknowledged that if patients similar to
them would have contributed to the trial design, and that
the trial demonstrated favorable results for a cardiovas-
cular medication, then the participants would be more
likely to comply with taking that medication. The active
participation of like-patients would help dispel skepticism
that the study was biased or influenced to yield positive
results. The general public might have more confidence in
the results, assuming that the patients who participate in
the study design would have interests and perspectives
similar to their own.
Discussion
There are both benefits and problems associated with
the use of composite endpoints. Though it is a validated
statistical tool, it can potentially be utilized to the ad-
vantage and vested interest of the sponsor or the inves-
tigators. In addition, its use can lead to conclusions and
clinical decisions that lack the precision of a single
endpoint. The choice to utilize a composite endpoint
trial design is usually made with the intention of reaching
a positive result in the shortest amount of time and
consuming the least amount of resources. As healthcare
resources are being curtailed, funding sources for clinical
trials will become scarcer, and the use of composite
endpoints will become more widespread.
Though patients may have harbored personal opinions
regarding study methodology based on their values and
experiences, there has not been an opportunity to for
patients to articulate their views regarding a preferred study
design. Patients and investigators might value potential
clinical outcomes or endpoints differently. If patients are
given an opportunity to voice their opinions regarding
study design and choice of component outcomes, such an
Table 5. Use of single vs. composite endpoints
Endpoint Responses
Single 43
Composite 57
Total 100
Table 6. Potential contributors to the study design
Contributors Responses
Researchers/scientists 41
Patient population 48
General public 11
Total 100
Table 7. Effect on participants’ potential compliance to a
cardiovascular medication if patients similar to participants
had contributed to the decision-making process for trial
design
Effect on compliance Responses
No effect 8
Small effect 25
Significant effect 39
Large/major effect 28
Total 100
Table 4. Choice of endpoint/s for a trial comparing two
heart medications
Endpoint/response No (%) Yes (%)
Heart attack 9 91
Death (heart disease) 48 52
Chest pain-hosp. 48 52
Angioplasty/PCI/CABG 54 46
Stroke 35 65
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results to future patients. Future studies may demonstrate
that patients can potentially make insightful recommen-
dations regarding the choice of endpoints as well as value
judgments regarding each proposed endpoint that is in
the best interest of patients. If patients select composite
outcomes as their preferred methodology for a given trial,
then they should also have a voice in designating the
specific component outcomes that should be included in
the composite. Finally, if the target population contri-
butes to the study design and selection of endpoints, this
may potentially impact the compliance of this population
with the study medications, once the study results are
disseminated. That is, the nature, design, and results
of any study will be perceived with greater validity if
participants’ perceptions are taken into account.
As medical treatments are becoming more sophisti-
cated and evidence-based, the opinions and preferences
of patients may be more challenging to integrate into
clinical research methodology. However, as noted by
Quill et al., who coined the term preference-based care,
good patient care is a delicate balance between evidence-
based care, patients’ preferences, and societal values (6).
We believe that the same concept can be extended to
clinical research, which has yet to directly embrace the
preferences of patients into its regular study design
decision-making process.
In our study, patients seemed to prefer the use of a com-
posite endpoint over single endpoints. However, those
with a higher level of education expressed a preference for
the single endpoint methodology. The reason is open to
speculation and provides cause for further investigation.
Further, our survey showed that it more important to
survey the patient population rather than the general
population regarding study methodology. The distinction
between these two groups seems to be important; the
former has insight into the disease experience and avested
interest in the outcome.
Finally, one criticism regarding composite endpoints is
the relative inequality among the endpoints. For example,
patients seem to value the endpoint of myocardial infarc-
tion with greater importance than hospitalization for
chest pain. Investigators have also lamented the choice
of unequal endpoints in composite endpoint trials (7).
However, it may be possible to adjudicate each element
of the composite endpoint with an empirically-derived
adjustment factor based on pre-stated patient preferences
and values. Thus, meeting a less-valued component of the
composite endpoint, such as hospitalization for chest
pain, may not necessarily mandate that the composite
endpoint has been reached. Such an approach would
require general acceptance from the entire scientific
community in terms of how such an approach might be
implemented.
This is pilot study and is limited by the small sample
size. In addition, our sample has a higher level of edu-
cation compared to the general U.S. population; 8% of
the U.S. population has a Master’s degree education
(9), compared to 34% of our sample. Further studies
with larger sample sizes would help confirm the need to
solicit patient input into the process of study design
development.
Conflict of interest and funding
The authors have not received any funding or benefits
from industry or elsewhere to conduct this study.
References
1. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC.
Deﬁnition, reporting, and interpretation of composite outcomes
in clinical trials: Systematic review. BMJ 2010; 341: c3920.
2. Phase 3 clinical trials exceed $26,000 per patient. Life Sciences
World. Oct 12, 2006. Available from: http://www.lifesciencesworld.
com/news/view/11080 [cited 25 November 2010].
3. Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite
outcomes in cardiovascular research: A survey of randomized
trials. Ann Intern Med 2008; 149: 6127.
4. Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM,
Akl EA, Bryant DM, et al. Problems with use of composite end
points in cardiovascular trials: Systematic review of randomised
controlled trials. BMJ 2007; 334: 786.
5. Freemantle N, Calvert M, Wood J, Eastaugh J, Grifﬁn C.
Composite outcomes in randomized trials: Greater precision
but with greater uncertainty? JAMA 2003; 289(19): 25549.
6. Quill TE, Holloway RG. Evidence, preferences, recommendations
 ﬁnding the right balance in patient care. N Engl J Med 2012;
366(18): 16535.
7. Albers GW. Choice of endpoints in antiplatelet trials: Which
outcomes are most relevant to stroke patients? Neurology 2000;
54: 10228.
8. Obtained from U.S. Census data. Available from: http://www.
census.gov/hhes/socdemo/education/data/cps/2012/tables.html
[cited 28 November 2013].
Patient preferences for endpoint selection
Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 22643 - http://dx.doi.org/10.3402/jchimp.v4.22643 5
(page number not for citation purpose)